Market Size of South America Kidney Cancer Therapeutics & Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 6.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
South America Kidney Cancer Therapeutics & Diagnostics Market Analysis
Kidney cancer is a disease that starts in the kidneys. It happens when healthy cells in one or both kidneys grow out of control and form a tumor. Renal cell carcinoma is the most common type of kidney cancer found in adults.
In South America, the cases of kidney cancer are on the rise. This has resulted in increasing demand for kidney therapeutics and diagnostics. Currently, there are various treatment options available and many drugs are in pipeline too, which is expected to drive the kidney cancer therapeutics and diagnostics market during the forecast period.
In addition, rising investments in research by various government bodies and the development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors. Hence all these factors are expected to help the growth of kidney cancer and therapeutics market in South America.
South America Kidney Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, kidney cancer is a type of cancer which starts in kidney cells. The kidney cancer therapeutics and diagnostics involves therapy and diagnostics methods that are used for the treatment of renal cancer. The drugs are used for the treatment of various type of kidney cancers.
| By Cancer Type | |
| Renal Cell Carcinoma | |
| Clear Cell Renal Cell Carcinoma | |
| Papillary Renal Cell Carcinoma | |
| Other Cancer Types |
| By Therapeutic Class | |
| Targeted Therapy | |
| Immunotherapy |
| By Pharmacologic Class | |
| Angiogenesis Inhibitors | |
| Monoclonal Antibodies | |
| mTOR Inhibitors | |
| Others |
| By Diagnostics | |
| Biopsy | |
| Intravenous Pyelogram | |
| CT Scan | |
| Ultrasound | |
| Other Diagnostics |
| Geography | |||||
|
South America Kidney Cancer Therapeutics & Diagnostics Market Size Summary
The South America kidney cancer therapeutics and diagnostics market is experiencing significant growth due to the increasing prevalence of kidney cancer, particularly renal cell carcinoma, which is the most common type among adults. The rise in kidney cancer cases has led to a heightened demand for effective therapeutics and diagnostics solutions. This demand is further fueled by the availability of various treatment options and the development of new drugs, which are expected to drive market expansion during the forecast period. Additionally, the region is witnessing increased investments in research by government bodies and advancements in drug development by pharmaceutical and biotechnology companies, contributing to the market's growth trajectory.
Despite being a developing region with varying levels of healthcare infrastructure, South American countries are progressively increasing their healthcare expenditures. This trend has attracted numerous global companies to the market, resulting in a competitive landscape with the presence of major players such as Eisai, Bristol Myers Squibb Company, Exelixis, Novartis International AG, and Bayer AG. The growing awareness of cancer, higher diagnostic rates, an aging population, and the rising incidence of renal cancer are also key factors driving the market. These dynamics indicate a robust growth potential for kidney cancer therapeutics and diagnostics in South America over the coming years.
South America Kidney Cancer Therapeutics & Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Number of Kidney Cancer Case
-
1.2.2 Increased R&D Expenditure of Pharmaceutical Companies
-
-
1.3 Market Restraints
-
1.3.1 High Cost Associated with Treatment
-
1.3.2 Low Success Rate in Clinical Trials for Cancer Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Cancer Type
-
2.1.1 Renal Cell Carcinoma
-
2.1.2 Clear Cell Renal Cell Carcinoma
-
2.1.3 Papillary Renal Cell Carcinoma
-
2.1.4 Other Cancer Types
-
-
2.2 By Therapeutic Class
-
2.2.1 Targeted Therapy
-
2.2.2 Immunotherapy
-
-
2.3 By Pharmacologic Class
-
2.3.1 Angiogenesis Inhibitors
-
2.3.2 Monoclonal Antibodies
-
2.3.3 mTOR Inhibitors
-
2.3.4 Others
-
-
2.4 By Diagnostics
-
2.4.1 Biopsy
-
2.4.2 Intravenous Pyelogram
-
2.4.3 CT Scan
-
2.4.4 Ultrasound
-
2.4.5 Other Diagnostics
-
-
2.5 Geography
-
2.5.1 South America
-
2.5.1.1 Brazil
-
2.5.1.2 Argentina
-
2.5.1.3 Rest of South America
-
-
-
South America Kidney Cancer Therapeutics & Diagnostics Market Size FAQs
What is the current South America Kidney Cancer Therapeutics & Diagnostics Market size?
The South America Kidney Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in South America Kidney Cancer Therapeutics & Diagnostics Market?
Eisai, Bristol Myers Squibb Company, Exelixis , Novartis International AG and Bayer AG are the major companies operating in the South America Kidney Cancer Therapeutics & Diagnostics Market.
